索拉非尼和125Ⅰ粒子植入分别治疗放射性碘难治性分化型甲状腺癌的效果对比
Comparative of the Effect of Sorafenib and 125Ⅰ Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer Patients with Radioactive Iodine
翟芊 1李宁 2付中华3
作者信息
- 1. 开封市中心医院核医学科,河南 开封 475000
- 2. 开封市中心医院肿瘤科二病区,河南 开封 475000
- 3. 开封市中心医院彩超室,河南 开封 475000
- 折叠
摘要
目的:探讨索拉非尼和 125Ⅰ粒子植入治疗放射性碘难治性分化型甲状腺癌患者的效果.方法:选取2020年2月—2022年5月本院诊治的放射性碘难治性分化型甲状腺癌患者56例作为研究对象,根据随机数字表法分为索拉非尼组与植入组,各28例.植入组给予 125Ⅰ粒子植入治疗,索拉菲尼组给予索拉非尼治疗,比较两组治疗3个月后疾病控制率、毒副作用发生率及血清因子表达.结果:治疗3个月后,索拉菲尼组的疾病控制率为85.72%,高于植入组的67.86%(P<0.05);索拉非尼组毒副作用发生率与植入组比较,差异无统计学意义(P>0.05);索拉非尼组血清IL-6、IL-8含量低于植入组(P<0.05).结论:相对于 125Ⅰ粒子植入治疗,索拉非尼治疗甲状腺癌患者能抑制肿瘤的进展,减轻临床症状,具有较高安全性.
Abstract
Objective:To investigate the effect of sorafenib and 125Ⅰ particle implantation in patients with radioiodine-refractory differentiated thyroid cancer.Methods:A total of 56 patients with radioactive iodine-refractory differentiated thyroid cancer diagnosed and treated in our hospital from February 2020 to May 2022 were selected as the research objects.According to the random number table method,they were divided into sorafenib group and implantation group,with 28 patients in each group.The implantation group was treated with 125Ⅰ seed implantation,and the sorafenib group was treated with sorafenib.The disease control rate,incidence of toxic and side effects and serum factor expression were compared between the two groups after 3 months of treatment.Result:After 3 months of treatment,the disease control rate of the sorafenib group was 85.72%,which was higher than 67.86%of the implantation group(P<0.05).There was no significant difference in the incidence of adverse reactions between the sorafenib group and the implantation group(P>0.05).The serum levels of IL-6 and IL-8 in the sorafenib group were lower than those in the implantation group(P<0.05).Conclusion:Compared with 125Ⅰ particle implantation treatment,sorafenib treatment can inhibit tumor progression in patients with thyroid cancer,reduce clinical symptoms,and has a high safety profile.
关键词
索拉非尼/125Ⅰ粒子植入治疗/甲状腺癌Key words
Sorafenib/125Ⅰ seed implantation therapy/Thyroid cancer引用本文复制引用
出版年
2024
NETL
NSTL
万方数据